This study explores how effective standard chemotherapy is alone or when combined with tocilizumab, a medication that blocks a protein called IL-6, in treating certain types of advanced breast cancer in Black and non-Black patients. Patients with triple-negative or ER-low breast cancer, which means their cancer doesn't have certain hormone receptors, may benefit from this treatment. Participants are randomly assigned to one of two groups: one receiving only chemotherapy and the other receiving chemotherapy plus tocilizumab. The study is divided into two stages, with the first stage including 42 patients per group.
- Duration: Two-stage study with possible early stopping if results are not promising.
- Visits: Regular visits are required for treatment and monitoring.
- Risks: Potential side effects from chemotherapy and tocilizumab.
How understandable was the trial content above?
Hard to understand
Easy to understand